Key facts
- 52-week range (closes)
- $269.75 – $388.35 Lowest close Sep 24, 2026, highest Oct 22, 2025; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- December Fiscal 2025 ended Dec 31, 2025, from SEC filings
- In the S&P 500 since
- Dec 12, 2000 · All S&P 500 changes
- Analyst coverage
- 5 open price targets from 5 firms: Canaccord Genuity, Citizens JMP, Needham, Stifel, Truist Securities Approved targets tracked here; see the analyst section below
Stryker Corporation (SYK) is trading up at $303.06 (+1.72%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on SYK
Current price targets from 5 firms average $369, median $385, ranging from $310 to $418 — the average is 22% above the current $303. Each is tracked to its date and scored the same way a member's call is.
- Truist Securities $278 → $310 by Oct 2027 Oct 6, 2026 via Investing.com · Truist Securities's track record
- Needham $278 → $418 by Oct 2027 Oct 6, 2026 via Investing.com · Needham's track record
- Stifel $275 → $330 by Sep 2027 Sep 29, 2026 via Investing.com · Stifel's track record
- Canaccord Genuity $280 → $385 by Sep 2027 Sep 17, 2026 via Investing.com · Canaccord Genuity's track record
- Citizens JMP $341 → $400 by Aug 2027 Aug 3, 2026 via Investing.com · Citizens JMP's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Stryker Corporation revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $11.3B | $12.4B | $13.6B | $14.9B | $14.4B | $17.1B | $18.4B | $20.5B | $22.6B | $25.1B |
| Growth (year over year) | +13.9% | +9.9% | +9.3% | +9.4% | −3.6% | +19.2% | +7.8% | +11.1% | +10.2% | +11.2% |
| Gross profit | $7.50B | $8.18B | $8.94B | $9.70B | $9.06B | $11.0B | $11.6B | $13.1B | $14.4B | $16.1B |
| Gross margin | 66.3% | 65.7% | 65.7% | 65.1% | 63.1% | 64.1% | 62.8% | 63.7% | 63.9% | 64.0% |
| Operating income | $2.17B | $2.30B | $2.54B | $2.71B | $2.22B | $2.58B | $2.84B | $3.89B | $3.69B | $4.89B |
| Operating margin | 19.2% | 18.5% | 18.7% | 18.2% | 15.5% | 15.1% | 15.4% | 19.0% | 16.3% | 19.5% |
| Net income | $1.65B | $1.02B | $3.55B | $2.08B | $1.60B | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B |
| Net margin | 14.5% | 8.2% | 26.1% | 14.0% | 11.1% | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% |
| EPS (diluted) | $4.35 | $2.68 | $9.34 | $5.48 | $4.20 | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 |
| Balance sheet | ||||||||||
| Cash and equivalents | $3.32B | $2.54B | $3.62B | $4.34B | $2.94B | $2.94B | $1.84B | $2.97B | $3.65B | $4.01B |
| Total assets | $20.4B | $22.2B | $27.2B | $30.2B | $34.3B | $34.6B | $36.9B | $39.9B | $43.0B | $47.8B |
| Total liabilities | $10.9B | $12.2B | $15.5B | $17.4B | $21.2B | $19.8B | $20.3B | $21.3B | $22.3B | $25.4B |
| Long-term debt | $6.69B | $6.59B | $8.49B | $10.2B | $13.2B | $12.5B | $11.9B | $10.9B | $12.2B | $14.9B |
| Shareholders' equity | $9.55B | $9.97B | $11.7B | $12.8B | $13.1B | $14.9B | $16.6B | $18.6B | $20.6B | $22.4B |
| Cash flow | ||||||||||
| Operating cash flow | $1.92B | $1.56B | $2.61B | $2.19B | $3.28B | $3.26B | $2.62B | $3.71B | $4.24B | $5.04B |
| Capital expenditure | $490.0M | $598.0M | $572.0M | $649.0M | $487.0M | $525.0M | $588.0M | $575.0M | $755.0M | $761.0M |
| Free cash flow | $1.43B | $961.0M | $2.04B | $1.54B | $2.79B | $2.74B | $2.04B | $3.14B | $3.49B | $4.28B |
| Dividends paid | $568.0M | $636.0M | $703.0M | $778.0M | $863.0M | $950.0M | $1.05B | $1.14B | $1.22B | $1.28B |
| Share buybacks | $13.0M | $230.0M | $300.0M | $307.0M | $0 | $0 | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.49B | $6.44B | $5.87B | $6.02B | $6.06B | $7.17B | $6.02B | $6.59B |
| Growth (year over year) | +11.9% | +10.7% | +11.9% | +11.1% | +10.2% | +11.4% | +2.6% | +9.4% |
| Gross profit | $3.52B | $4.17B | $3.74B | $3.84B | $3.85B | $4.63B | $3.81B | $4.50B |
| Gross margin | 64.0% | 64.9% | 63.8% | 63.8% | 63.6% | 64.5% | 63.3% | 68.3% |
| Operating income | $1.08B | $581.0M | $837.0M | $1.11B | $1.14B | $1.80B | $936.0M | $1.66B |
| Operating margin | 19.7% | 9.0% | 14.3% | 18.5% | 18.7% | 25.2% | 15.5% | 25.2% |
| Net income | $834.0M | $546.0M | $654.0M | $884.0M | $859.0M | $849.0M | $745.0M | $1.28B |
| Net margin | 15.2% | 8.5% | 11.1% | 14.7% | 14.2% | 11.8% | 12.4% | 19.4% |
| EPS (diluted) | $2.16 | $1.41 | $1.69 | $2.29 | $2.22 | $2.20 | $1.93 | $3.30 |
| Balance sheet | ||||||||
| Cash and equivalents | $3.85B | $3.65B | $2.32B | $2.38B | $3.26B | $4.01B | $2.88B | $3.39B |
| Total assets | $43.8B | $43.0B | $46.0B | $46.3B | $47.1B | $47.8B | $46.3B | $47.9B |
| Total liabilities | $23.7B | $22.3B | $25.1B | $25.1B | $25.3B | $25.4B | $23.3B | $23.9B |
| Long-term debt | $13.3B | $12.2B | $14.4B | $14.8B | $14.8B | $14.9B | $14.2B | $14.2B |
| Shareholders' equity | $20.1B | $20.6B | $20.9B | $21.2B | $21.8B | $22.4B | $23.0B | $24.0B |
| Cash flow | ||||||||
| Operating cash flow | $1.47B | $1.93B | $250.0M | $1.11B | $1.54B | $2.14B | $581.0M | $1.26B |
| Capital expenditure | $170.0M | $266.0M | $123.0M | $183.0M | $187.0M | $268.0M | $166.0M | $202.0M |
| Free cash flow | $1.30B | $1.67B | $127.0M | $928.0M | $1.35B | $1.88B | $415.0M | $1.06B |
| Dividends paid | $305.0M | $305.0M | $320.0M | $321.0M | $322.0M | $321.0M | $337.0M | $337.0M |
From Stryker Corporation's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Stryker Corporation vs the Health Care sector and the S&P 500
Stryker Corporation's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Stryker Corporation | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +11.2% | +7.1% | +7.0% |
| Net margin, latest fiscal year | 12.9% | 13.1% | 12.9% |
| Share price change, 1 year | −21.8% | +19.8% | +5.9% |
Stryker Corporation: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Stryker Corporation included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.
About Stryker Corporation
Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. The company's products are used for medical surgery and neurotechnology, which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery, which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States.
Source: Wikipedia — Stryker Corporation
- Headquarters
- Portage, Michigan From SEC filings, Oct 2026
Recent News (20)
-
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal Stryker has received FDA 510(k) clearance for Sonopet® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers en…
-
Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery Portage, Mich., USA and Cambridge, England, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Strategic alliance combines CMR Surgical’s established platform and robotics expertise with Stryker’s scale, customer…
-
Baird reiterates Stryker stock rating on planned CEO transition
Baird reiterates Stryker stock rating on planned CEO transition
-
Truist cuts Stryker stock price target on revised forecasts
Truist cuts Stryker stock price target on revised forecasts
-
Needham reiterates Buy on Stryker stock after CEO transition plan
Needham reiterates Buy on Stryker stock after CEO transition plan
-
Stryker shares dip on CEO transition despite orderly succession plan
Stryker shares dip on CEO transition despite orderly succession plan
-
Stryker names Spencer Stiles CEO as Kevin Lobo moves to chair
Stryker names Spencer Stiles CEO as Kevin Lobo moves to chair
-
Stryker announces leadership succession Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will tra…
-
-
Stifel cuts Stryker stock price target on revenue pressures
Stifel cuts Stryker stock price target on revenue pressures
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact D…
-
Canaccord cuts Stryker stock price target on manufacturing woes
Canaccord cuts Stryker stock price target on manufacturing woes
-
-
GEHC vs. SYK pairs trade: valuation gap and relative value case
GEHC vs. SYK pairs trade: valuation gap and relative value case
-
-
Stryker: Operational Issues Have Created An Opportunity (NYSE:SYK) Stryker: Operational Issues Have Created An Opportunity (NYSE:SYK) Seeking Alpha
-
9/8/2026 S&P 500 Update - Winners: LITE, INTC, HPE - Losers: HWM, AMGN, SYK - S&P 500: -0.6% 9/8/2026 S&P 500 Update - Winners: LITE, INTC, HPE - Losers: HWM, AMGN, SYK - S&P 500: -0.6% Trefis
-
S&P 500 Movers | Winners: LITE, INTC, HPE | Losers: HWM, AMGN, SYK S&P 500 Movers | Winners: LITE, INTC, HPE | Losers: HWM, AMGN, SYK trefis.com
-
Stryker at wells fargo healthcare conference: growth tested by supply
Stryker at wells fargo healthcare conference: growth tested by supply
-
More Health Care stocks
- RMD ResMed
- RVTY Revvity
- SOLV Solventum
- STE Steris
- TECH Bio-Techne
- TMO Thermo Fisher Scientific
- UHS Universal Health Services
- UNH UnitedHealth Group